David Cole to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications David Cole has written about Antimetabolites, Antineoplastic.
Connection Strength
0.125
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.102
-
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
Score: 0.023